Video Gallery
Fundamentals of the IMMray™ PanCan-d test
Clinical Diagnosis & Diagnostic Aids for Pancreatic Cancer
Presented by Thomas C. King, MD, PhD, Medical Director
Published February 17, 2021
Current Diagnostic Landscape for Pancreatic Cancer (PDAC)
Presented by Thomas C. King, MD, PhD, Medical Director
Published February 17, 2021
Laboratory Developed Tests
Presented by Thomas C. King, MD, PhD, Medical Director
Published February 17, 2021
Statistical Evaluation of Diagnostic Tests
Presented by Thomas C. King, MD, PhD, Medical Director
Published February 17, 2021
Familial/Hereditary Pancreatic Cancer Surveillance Programs: An Overview
Presented by Carrie Mansfield, MBA, Clinical Marketing Program Manager
Published February 17, 2021
Reimbursement in the US: An Overview
Presented by Karen Rego, MS, Sales Operations and Payer Relations Manager
Published February 17, 2021
Other Immunovia videos
Immunovia’s pancreatic cancer awareness campaign between August 12 to September 30, 2019 in Times Square, New York City, highlighting the importance of early detection.
WCVB Channel 5 News covered on the 2nd of May 2019, 5 pm EST Immunovia’s IMMray™ PanCan-d for early detection of pancreatic cancer: “Promising results reported for early detection blood test targeting pancreatic cancer”.
IMMray™ technology:
IMMray™ PanCan–d is the first blood-based test for early and specific (differential) diagnosis, providing clinicians with actionable information. Immunovia has defined a clinically relevant condensed panel of serum biomarkers (a biomarker signature) associated with pancreatic adenocarcinoma. Published January 2016.
IMMray™ technology – Short Version:
IMMray™ PanCan–d is the first blood-based test for early and specific (differential) diagnosis, providing clinicians with actionable information. Immunovia has defined a clinically relevant condensed panel of serum biomarkers (a biomarker signature) associated with pancreatic adenocarcinoma. Published November 2015.
